
Keywords: alopecia areata; atopic dermatitis; baricitinib; dermatology; graft versus host disease; JAK inhibitors; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AE; adverse event; CANDLE; chronic atypical neutrophilic de